About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6605 record(s)
Req # A-2020-001592
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03346550.Organization: Health Canada
April 2021
Req # A-2020-001593
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03352275.Organization: Health Canada
April 2021
Req # A-2020-001594
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03232927.Organization: Health Canada
April 2021
Req # A-2020-001603
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03331704.Organization: Health Canada
April 2021
Req # A-2020-001632
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_02581310.Organization: Health Canada
April 2021
Req # A-2020-001640
Adverse Drug Reaction (ADR) for CLOPIDOGREL BISUFATE. Report number: E2B_03194814.Organization: Health Canada
April 2021
Req # A-2020-001644
Adverse Reaction Reports (AERs) for DOCETAXEL. Report numbers: 000914051, 000914734, 000915553, 000916674, 000918041, 000918235, 000918490, 000919057, E2B_03216982, E2B_03221746, E2B_03273695.Organization: Health Canada
April 2021
Req # A-2020-001648
Adverse Reaction Reports (AERs) for FLUDARABINE PHOSPHATE. Report numbers: 916612, 916731, 000916759, 000917438, 000917442, 000917458, 000917448, 000917690, 000917819, 000918479.Organization: Health Canada
April 2021
Req # A-2020-001649
Adverse Reaction Reports (AERs) for RIFAMPICIN. Report numbers: 000914884, E2B_03183672, E2B_03183681.Organization: Health Canada
April 2021
Req # A-2020-001661
Adverse Reaction Reports (AERs) for TYLENOL. Report numbers: 000908288, 000916671, 0009917413. (ADR) for TYLENOL COMPLETE COLD, COUGH & FLU. Report number: 00090333. (ADR) for TYLENOL EXTRA STRENGTH CAPLETS. Report number: 000912956. (ADR)…Organization: Health Canada
April 2021